Celldex Therapeutics Inc. [NASDAQ: CLDX] closed the trading session at $4.80 on 06/10/20. The day’s price range saw the stock hit a low of $3.2835, while the highest price level was $5.70. The stocks have a year to date performance of 115.25 percent and weekly performance of 52.38 percent. The stock has been moved at 108.70 percent over the last six months. The stock has performed 100.84 percent around the most recent 30 days and changed 136.45 percent over the most recent 3-months.
If compared to the average trading volume of 451.85K shares, CLDX reached to a volume of 23064962 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Here’s what leading stock market gurus have to say about Celldex Therapeutics Inc. [CLDX]:
Cantor Fitzgerald have made an estimate for Celldex Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 21, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 01, 2017, representing the official price target for Celldex Therapeutics Inc. stock.
The Average True Range (ATR) for Celldex Therapeutics Inc. is set at 0.40, with the Price to Sales ratio for CLDX stock in the period of the last 12 months amounting to 18.80. The Price to Book ratio for the last quarter was 1.00, with the Price to Cash per share for the same quarter was set at 2.80.
CLDX stock trade performance evaluation
Celldex Therapeutics Inc. [CLDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 52.38. With this latest performance, CLDX shares gained by 100.84% in over the last four-week period, additionally plugging by 108.70% over the last 6 months – not to mention a rise of 90.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLDX stock in for the last two-week period is set at 87.02, with the RSI for the last a single of trading hit 90.68, and the three-weeks RSI is set at 82.29 for Celldex Therapeutics Inc. [CLDX]. The present Moving Average for the last 50 days of trading for this stock 2.41, while it was recorded at 3.42 for the last single week of trading, and 2.32 for the last 200 days.
Celldex Therapeutics Inc. [CLDX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Celldex Therapeutics Inc. [CLDX] shares currently have an operating margin of -1526.03. Celldex Therapeutics Inc.’s Net Margin is presently recorded at -1423.96.
Return on Total Capital for CLDX is now -49.18, given the latest momentum, and Return on Invested Capital for the company is -46.30. Return on Equity for this stock declined to -46.66, with Return on Assets sitting at -36.51. When it comes to the capital structure of this company, Celldex Therapeutics Inc. [CLDX] has a Total Debt to Total Equity ratio set at 3.89. Additionally, CLDX Total Debt to Total Capital is recorded at 3.74, with Total Debt to Total Assets ending up at 2.97. Long-Term Debt to Equity for the company is recorded at 1.82, with the Long-Term Debt to Total Capital now at 1.75.
Reflecting on the efficiency of the workforce at the company, Celldex Therapeutics Inc. [CLDX] managed to generate an average of -$391,369 per employee. Receivables Turnover for the company is 1.60 with a Total Asset Turnover recorded at a value of 0.03.Celldex Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.10 and a Current Ratio set at 5.10.
Earnings per share (EPS) analysis for Celldex Therapeutics Inc. [CLDX] stock
With the latest financial reports released by the company, Celldex Therapeutics Inc. posted -0.84/share EPS, while the average EPS was predicted by analysts to be reported at -1.17/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 28.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLDX.
Celldex Therapeutics Inc. [CLDX]: Insider Ownership positions
There are presently around $12 million, or 23.40% of CLDX stock, in the hands of institutional investors. The top three institutional holders of CLDX stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,170,187, which is approximately 4.915% of the company’s market cap and around 0.19% of the total institutional ownership; VANGUARD GROUP INC, holding 537,928 shares of the stock with an approximate value of $1.61 million in CLDX stocks shares; and CRESSET ASSET MANAGEMENT, LLC, currently with $1.37 million in CLDX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Celldex Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 17 institutional holders increased their position in Celldex Therapeutics Inc. [NASDAQ:CLDX] by around 200,185 shares. Additionally, 19 investors decreased positions by around 210,048 shares, while 18 investors held positions by with 3,563,443 shares. The mentioned changes placed institutional holdings at 3,973,676 shares, according to the latest SEC report filing. CLDX stock had 6 new institutional investments in for a total of 49,147 shares, while 9 institutional investors sold positions of 130,254 shares during the same period.